Development and manufacturing services provider PCT has expanded its relationship with Kiadis Pharma by entering into an agreement for the manufacturing of cell therapy product for U.S. and Canada clinical trial sites for a Phase 3 trial of Kiadis’ lead product, ATIR101, for the treatment of blood cancers. PCT is a subsidiary of cell therapy company Caldrius Biosciences. To date, PCT has provided engineering and process development services for Kiadis, which included optimizing its manufac...